Telomir Shares Surge 28% After Breakthrough Preclinical Age-Reversal Data
By ATTN Desk · Editorial oversight: Sean Han
Introduction to Telomir Pharmaceuticals Inc
Telomir Pharmaceuticals Inc (NASDAQ: TELO) is a pre-clinical stage biotechnology company headquartered in Tampa, Florida. Founded in 2022, the firm is developing Telomir-1, an oral small molecule intended to regulate essential metals, extend telomere caps, and address oxidative stress, DNA damage, chronic inflammation, and mitochondrial dysfunction.
Corporate Structure and Expertise
With a team of fewer than 10 employees, Telomir maintains an advisory panel of 14 experts in fields including medicine, ethics, public relations, law, and economics. Key executives include Erez Aminov (Chairman & CEO), Dr. Chris Chapman (Co-founder, Chairman, CEO & CMO), Dr. Michael Roizen (Age Reversal Advisor), and Dr. Itzchak Angel (Chief Scientific Advisor). The company collaborates with Nagi Biosciences SA to utilize advanced in vivo microfluidic assays.
Telomere research by Sangharsh Lohakare
Developments and Milestones
On February 8, 2024, Telomir priced an initial public offering of 1,000,000 shares at $7.00 per share. Its common stock began trading on the Nasdaq Capital Market on February 9, 2024 under the ticker “TELO.” Gross proceeds were expected to total $7 million, with underwriters holding a 45-day option for an additional 150,000 shares.
During a National Press Club event on April 15, 2024, Dr. Chapman and Dr. Roizen presented pre-clinical findings indicating a 40 percent enhancement in telomerase activity and telomere extension in human cell studies. Animal studies reported improvements in gait, joint health, weight-bearing capacity, and mitochondrial function markers.
On November 21, 2024, Telomir reported age-reversal effects in Caenorhabditis elegans using in vivo microfluidic technology, demonstrating extended lifespan, improved mobility, and measurable reversal of biological aging markers. Additionally, a zebrafish model of age-related macular degeneration showed restoration of retinal architecture and vision after a 14-day oral dosing regimen of Telomir-1.
Financial and Strategic Analysis
As of August 27, 2025, TELO closed at $1.8998, reflecting a 28.36 percent increase on that day, with a volume of 6,662,247 shares traded on the Nasdaq. Intraday market capitalization stood at $47.78 million and enterprise value at $47.88 million. Key metrics from Yahoo Finance include:
| Metric | Value |
|---|---|
| Previous Close (Aug 27, 2025) | $1.49 |
| 52-Week Range | $1.12 – $8.40 |
| EPS (TTM) | -$0.54 |
| Total Cash (mrq) | $0.75 million |
| Total Debt/Equity (mrq) | 19.42 percent |
| Price/Book (mrq) | 99.28 |
| 1-Year Target Estimate | $15.50 |
| Earnings Date | Aug 11 – 15, 2025 |
The company has reported net losses attributed to R&D expenditures and maintains limited cash reserves. The absence of revenue and reliance on external financing emphasizes the importance of future capital raises, including potential debt or equity offerings, to fund Investigational New Drug (IND) applications and Phase I clinical trials.
Market Position and Industry Context
Telomir operates in the field of age-reversal science, targeting various pathways implicated in aging and chronic disease. According to the Synapse Database (April 18, 2024), 83 investigational drugs target the IL-17 pathway, spanning 95 indications, 732 clinical trials, and 425 patents. Telomir-1 is positioned for osteoarthritis and inflammation and is currently in the pre-clinical phase. The company’s broad focus covers conditions such as hemochromatosis, age-related macular degeneration, osteoarthritis, and progeria, aiming to address both cellular senescence and systemic degeneration. Collaborations with research contract research organizations (CROs) such as Eurofins Discovery and Nagi Biosciences support pre-clinical validation. Ongoing SEC filings (Form 8-K on August 7 and 27, 2025; Form 10-Q on August 14, 2025) provide periodic disclosures of corporate events.
tl;dr
As of August 28, 2025, TELO shares rose 28.36 percent to $1.8998 on volume of 6.7 million. The company completed a $7 million IPO in February 2024 and has published pre-clinical data (April 15, 2024; November 21, 2024) showing telomerase activation, extended telomeres, and functional restoration in aging models. With cash of $0.75 million and negative EPS of $0.54, Telomir awaits IND clearance and Phase I trials. Earnings are scheduled for August 11–15, 2025, and the 1-year analyst target is $15.50. Ongoing R&D collaborations and planned capital raises will be crucial for advancing Telomir-1 into clinical development.